Tourmaline Bio Statistics

Total Valuation

Tourmaline Bio has a market cap or net worth of $377.26 million. The enterprise value is $84.35 million.

Market Cap	377.26M
Enterprise Value	84.35M

Important Dates

The next estimated earnings date is Thursday, August 15, 2024, before market open.

Earnings Date	Aug 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Tourmaline Bio has 25.65 million shares outstanding. The number of shares has increased by 2,558.06% in one year.

Shares Outstanding	25.65M
Shares Change (YoY)	+2,558.06%
Shares Change (QoQ)	+407.31%
Owned by Insiders (%)	15.51%
Owned by Institutions (%)	25.95%
Float	13.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.07
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 62.17, with a Debt / Equity ratio of 0.00.

Current Ratio	62.17
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -15.50% and return on invested capital (ROIC) is -10.96%.

Return on Equity (ROE)	-15.50%
Return on Assets (ROA)	-15.00%
Return on Capital (ROIC)	-10.96%
Revenue Per Employee	n/a
Profits Per Employee	-$748,591
Employee Count	44
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.13% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-51.13%
50-Day Moving Average	14.39
200-Day Moving Average	22.98
Relative Strength Index (RSI)	51.91
Average Volume (20 Days)	416,926

Short Selling Information

The latest short interest is 1.53 million, so 5.97% of the outstanding shares have been sold short.

Short Interest	1.53M
Short Previous Month	2.64M
Short % of Shares Out	5.97%
Short % of Float	11.36%
Short Ratio (days to cover)	2.04

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-38.85M
Pretax Income	-32.94M
Net Income	-32.94M
EBITDA	-33.37M
EBIT	-32.94M
Earnings Per Share (EPS)	-$4.08

Full Income Statement

Balance Sheet

The company has $293.29 million in cash and $376,000 in debt, giving a net cash position of $292.91 million or $11.42 per share.

Cash & Cash Equivalents	293.29M
Total Debt	376,000
Net Cash	292.91M
Net Cash Per Share	$11.42
Equity (Book Value)	354.14M
Book Value Per Share	13.81
Working Capital	295.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$26.10 million and capital expenditures $264,000, giving a free cash flow of -$25.84 million.

Operating Cash Flow	-26.10M
Capital Expenditures	264,000
Free Cash Flow	-25.84M
FCF Per Share	-$1.07

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Tourmaline Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2,558.06%
Shareholder Yield	-2,558.06%
Earnings Yield	-8.73%
FCF Yield	-6.85%

Dividend Details

Analyst Forecast

The average price target for Tourmaline Bio is $61.80, which is 320.12% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$61.80
Price Target Difference	320.12%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-27.13%

Stock Forecasts

Stock Splits

The last stock split was on October 20, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	Oct 20, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	3